Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares rose 3.2% during mid-day trading on Wednesday . The company traded as high as $4.97 and last traded at $4.58. Approximately 40,752 shares were traded during trading, an increase of 1,782% from the average daily volume of 2,165 shares. The stock had previously closed at $4.44.
Graybug Vision Price Performance
The firm’s 50-day moving average price is $5.04 and its 200-day moving average price is $4.68. The stock has a market cap of $7.68 million, a P/E ratio of -0.20 and a beta of 1.20.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Stories
- Five stocks we like better than Graybug Vision
- How to Invest in the FAANG Stocks
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- What Does a Stock Split Mean?
- This Financial Stock’s Earnings Signal a Buying Opportunity
- Why is the Ex-Dividend Date Significant to Investors?
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.